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Abstract: Objective Older adults are among the most frequent users of emergency departments (EDs).
Nonspecific symptoms, such as fatigue and widespread pain, are among the most common symptoms in
patients admitted at the ED. Interleukin 6 (IL-6) and tumor necrosis factor ฀ (TNF-฀) are inflammation
biomarkers associated with chronic stress (i.e., dementia caregiving) and nonspecific symptoms. This
study aimed to determine whether IL-6 and TNF-฀ were prospectively associated with ED risk in dementia
caregivers (CGs). Methods Participants were 85 dementia CGs, who reported during three assessments
(3, 9, and 15 months after enrollment) if they had visited an ED for any reason. Cox proportional
hazards models were used to examine the relations between resting circulating levels of IL-6 and TNF-฀
obtained at enrollment and subsequent risk for an ED visit, adjusting for age, sex, use of ED 1 month
before enrollment, physical and mental health well-being, body mass index, and CG demands. Results
(log) IL-6 significantly predicted ED visits during the 15-month follow-up (B = 1.96, SE = 0.82, p =
.017). For every (log) picogram per milliliter increase in IL-6, the risk of visiting an ED was 7.10 times
greater. TNF-฀ was not associated with subsequent ED visits. Exploratory analyses suggested that CGs
with levels of IL-6 above the 80th percentile and experiencing high CG demands were at highest risk
of an ED visit. Conclusions IL-6 levels and CG demands may be useful for predicting vulnerability for
future ED visits. Although further studies should be conducted to replicate and extend these findings,
interventions that successfully modify inflammation markers, including the underlying pathophysiology
related to stress and/or comorbid illnesses, may be useful in preventing costly and detrimental outcomes
in this population.
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ABSTRACT
Objective: Older adults are among the most frequent users of emergency departments (EDs). Nonspecific symptoms, such as fatigue and
widespread pain, are among the most common symptoms in patients admitted at the ED. Interleukin 6 (IL-6) and tumor necrosis factor α
(TNF-α) are inflammation biomarkers associated with chronic stress (i.e., dementia caregiving) and nonspecific symptoms. This study
aimed to determine whether IL-6 and TNF-α were prospectively associated with ED risk in dementia caregivers (CGs).
Methods: Participants were 85 dementia CGs, who reported during three assessments (3, 9, and 15 months after enrollment) if they had
visited an ED for any reason. Cox proportional hazards models were used to examine the relations between resting circulating levels of
IL-6 and TNF-α obtained at enrollment and subsequent risk for an ED visit, adjusting for age, sex, use of ED 1 month before enrollment,
physical and mental health well-being, body mass index, and CG demands.
Results: (log) IL-6 significantly predicted ED visits during the 15-month follow-up (B = 1.96, SE = 0.82, p = .017). For every (log) pico-
gram per milliliter increase in IL-6, the risk of visiting an EDwas 7.10 times greater. TNF-αwas not associated with subsequent ED visits.
Exploratory analyses suggested that CGs with levels of IL-6 above the 80th percentile and experiencing high CG demands were at highest
risk of an ED visit.
Conclusions: IL-6 levels and CG demands may be useful for predicting vulnerability for future ED visits. Although further studies should be
conducted to replicate and extend these findings, interventions that successfully modify inflammationmarkers, including the underlying path-
ophysiology related to stress and/or comorbid illnesses, may be useful in preventing costly and detrimental outcomes in this population.
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INTRODUCTION
Caring for a loved one with dementia has been shown to in-crease risk for hypertension (1), cardiovascular diseases (2),
and immune system dysfunction (3–5). Furthermore, the intensity
of demands within caregiver (CG) populations has been shown to
increase health risks, such that CGs with higher demands andmen-
tal health vulnerabilities are at greater health risk (2,6). Caregivers
have been shown to have greater levels of stress and depression,
and lower levels of subjective well-being, physical health, and
self-efficacy compared with non-CGs (7). Caring for a family
member with dementia is particularly stressful and burdensome.
Dementia CGs spend more hours per week providing care and
assisting with more activities of daily living (ADLs) and instru-
mental ADL relative to nondementia CGs (8). Dementia CGs have
also reported higher emotional and physical strain, as well as fi-
nancial hardship compared with nondementia CGs, with dementia
status of the care recipient being a significant predictor of all three
(8). Chronic stress experienced by dementia caregiving has been
associated with impaired immune function (9). For instance, de-
mentia CGs had worse immune response to influenza virus vacci-
nation than matched non-CG control participants (4). In addition,
women caring for a family member with dementia showed slower
wound healing compared with controls (5). In another study, spou-
sal dementia CGs experiencing chronic stress had reduced lym-
phocyte sensitivity to glucocorticoids and increased salivary
cortisol compared with non-CGs (10). In addition, spousal demen-
tia CGs have demonstrated higher levels of plasma interleukin 6
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(IL-6) and D-dimer relative to non-CG controls (11). These stresses
of caregiving, and in particular the health consequences that result,
have the potential to place CGs at elevated risk for increased health-
care utilization, such as emergency department (ED) visits.
In 2014, Americans made 137.8 million visits to EDs, an in-
crease of 14.8% since 2006 (12). The rate of ED visits was highest
among individuals 65 years and older, at 538.3 visits per 1000
population (12). In 2016, the average cost of an ED visit was US
$1917, and ED visits accounted for 23% of all outpatient medical
expenditures, second only to outpatient surgeries (13). Nonspe-
cific symptoms (14) rank among the top reasons for ED visits in
all age groups. These symptoms include chest pain, abdominal
and back pain, shortness of breath, and weakness (12,15). Because
the origin of these symptoms is difficult to determine, prediction of
who will make ED visits becomes challenging, as does treatment.
Recent evidence suggests that acute somatic experiences, such
as pain (16), fatigue (17), aches and pains, and muscular tension
(18), are associated with increases in inflammation biomarkers, in-
cluding IL-6. IL-6 is a glycoprotein produced by a variety of lym-
phoid and nonlymphoid cells (19) and is easily determined by
standardized assays. IL-6 is involved as a proinflammatory cyto-
kine in the acute phase response to activating stimuli, such as in-
fection or tissue injury (20). During the acute phase response,
IL-6 can induce other acute phase proteins, such as fibrinogen,
serum amyloid A, and C-reactive protein (21). It also plays a
role in the activation of the hypothalamic pituitary adrenal axis
and regulation of hematopoiesis (19). Indeed, acute psycholog-
ical stress is known to produce a transient rise in peripheral cyto-
kines (22–24), including IL-6 (25). Furthermore, chronic stress,
such as experienced by dementia CGs, is associated with elevated
IL-6 concentrations (11,26,27).
Several studies demonstrate that IL-6 contributes to nociceptor
and central sensitization (28–30), and IL-6 levels increase after
nerve injury (31,32). In individuals with lumbar radicular pain,
higher serum IL-6 levels were associated with higher visual analog
scale scores for low back pain and leg pain (33). Other research
demonstrates that elevations in IL-6 are associated with “sickness
behaviors,” including complaints of headache, tired muscles, ex-
cessive fatigue, and self-reported fever (34). Therefore, we postu-
lated that elevations in IL-6 might be a biomarker associated with
symptoms driving visits to the ED.
In addition to explaining nonspecific symptoms, elevations in
IL-6 levels have been implicated in risk for various health condi-
tions and diseases (19) that may prompt ED visits. For example,
elevated levels of IL-6 have been associated with future risk for
stroke occurrence (35,36) as well as risk for other cardiovascular
events, such as acute myocardial infarction, coronary heart disease,
and congestive heart failure events (36). IL-6 is a significant predictor
of all-cause and cardiovascular mortality (37). Higher circulating IL-6
levels have also been shown to predict disability onset among older
adults (38), and among patients with community-acquired
pneumonia, elevated IL-6 levels are associated with mortality
risk (39).
Given the association of IL-6 levels with illness symptoms and
diseases potentially associated with ED visits, we sought to exam-
ine whether IL-6 is a useful prognostic indicator of ED visits in a
chronically stressed population of dementia CGs. We hypothe-
sized that among dementia CGs, IL-6 would be prospectively as-
sociated with 15-month ED visit risk.
METHODS
Participants
Participants were 85 dementia CGs enrolled in the University of California
San Diego (UC San Diego) Alzheimer’s Caregiver Study; a clinical trial
evaluating the effects of psychosocial treatments on psychosocial and car-
diovascular disease (CVD) risk outcomes in CGs. Our laboratory has pre-
viously investigated psychological and biological mechanisms of CVD in
CGs, including a clinical trial examining CVD risk (40). However, all par-
ticipants in this study were new to our research and had not participated in
any of our previous studies of CGs.
To be eligible, participants were required to be at least 55 years of age,
providing at least 20 hours/week of in-home care to a spouse with a physi-
cian diagnosis of dementia, and endorse at least mild depressive symptoms
(i.e., mild level of distress) as per a score of 5 or higher on the Patient Health
Questionnaire 9 (41) at the time of enrollment. Caregivers were excluded if
(a) either they or their care receivers were diagnosed with a terminal illness
with a life expectancy of less than one year, (b) they lacked capacity to con-
sent to the research project, (c) they were enrolled in another formal interven-
tion study or were receiving psychotherapy to improve well-being or reduce
distress, (d) they had blood pressure greater than 200/120mmHg (i.e., severe
hypertension), or (e) they received a diagnosis of cancer, heart failure, myo-
cardial infarction, or stroke in the 12 months before enrollment in the study.
All participants were recruited through outreach to local community
agencies serving older adults and/or CGs, community health fairs, and
through referrals from enrolled participants or dementia-specific agencies,
such as the UC San Diego Alzheimer’s Disease Research Center. Partici-
pants were enrolled between February 2015 and April 2017, and follow-
up data collection was completed for all participants by July 2018. All
CGs provided informed consent to participating in the study, which was ap-
proved by the UC San Diego Institutional Review Board.
Measures
Health Service Use
The use of emergencymedical services and overnight hospitalizations were
the key healthcare services assessed in the current study. Participants were
asked at intake (baseline), 3-, 9-, and 15-month assessments if they had vis-
ited an ED or urgent care clinic (for themselves, not for their care receivers)
or been hospitalized overnight during the previous assessment period (or up
to 1month before the baseline assessment). Because dates of ED or hospital
visits were not requested, the date of the interview was used as the visit
date. Visits to a walk-in clinic were not included as an emergency visit. Par-
ticipants answering in the affirmative were given a score of “1,” and partic-
ipants who had not used these services were given a score of “0.” The
dependent variables in our analyses were either days from baseline to first
ED visit or days to hospitalization.
Interleukin 6
Blood was collected at the baseline assessment by a research nurse in the CGs’
homes through a 22-gauge forearm catheter after a 20-minute rest.We collected
blood in EDTA tubes and later centrifuged for 15 minutes at 1732 relative cen-
trifugal force at 4°C. Plasma was stored at −80°C until analyzed. The level of
cytokine IL-6 was measured using an electrochemiluminescence-based
multiarray method through the Quickplex SQ 120 system (Meso Scale Di-
agnostics LLC, Rockville, MD). We used the human proinflammatory
panel-1 10-plex kits to detect two cytokines, IL-6, and tumor necrosis fac-
tor α (TNF-α). The system uses 96-well–based high throughput readout.
Fifty microliters of prepared plasma samples or calibrator was added into
the corresponding wells. The array was then incubated at room temperature
with shaking for 2 hours and then washed three times with PBS containing
0.05% Tween 20. Thereafter, 25 μl of detection antibody solution was
added with 2 hours of incubation at room temperature. After rinsing, 2
read buffer was added and the signals were detected by a Quickplex SQ
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120 system. IL-6 concentrations in the samples were determinedwithMSD
Discovery Workbench (Version 4) software, using curve fit mode. Intra-
and interassay coefficients of variation were less than 10%.
Caregiver Physical and Mental Well-being
Caregiver physical and mental well-being was assessed using the physical
composite score (PCS) and mental composite score (MCS) of short-form-
12 (SF-12) health questionnaire (42). The SF-12 is a global health measure
that assesses multiple areas of physical and mental health functioning regard-
less of age or disease. The PCS was created by summing factor-weighted
scores across four functioning domains (i.e., physical functioning, role phys-
ical, which indicates the impact of physical health symptoms on everyday
functioning, bodily pain, and general health), with higher scores representing
better physical health. The MCS was created by summing weighted scores
across the four domains of vitality, social functioning, role emotional,
which indicates the impact of emotional symptoms on everyday function-
ing, and mental health scales.
Caregiver Demands
Functional impairment of care receivers was used as an indicator of CG de-
mands. Caregivers were administered the Activities of Daily Living Ques-
tionnaire (ADLQ) (43), which contains 28 items assessing their care
receivers’ impairment in six areas encompassing self-care, household, em-
ployment, shopping, travel, and communication. All items are scored from
0 to 3, with higher scores reflecting greater impairment in that area of func-
tioning. The total scale score expresses an individual’s percent impairment
in performing ADL.
Caregiver Demographics and Health Characteristics
We collected CGs’ age, sex, and ethnicity/race. All participants were
weighed and had height measured by the research nurse for body mass in-
dex (BMI) computation.
Statistical Analysis
Cox proportional hazards regression was used to determine the relationship
between baseline continuous IL-6 values and prospective ED visit or hos-
pitalization. Initial (unadjusted) models were used and included only (log)
IL-6 as a predictor of outcomes. Subsequent models adjusted for the fol-
lowing demographic and health characteristics: age, sex, use of ED (or hos-
pitalization) in the 1month before enrollment, SF-12 PCS and SF-12MCS,
BMI, and CG demands. “Survival” time was the number of days between
the baseline interview and the last interview or to the date of first ED visit/
hospitalization. For variables in the model, hazard ratios (HRs) were com-
puted as the primarymeasure of effect, along with their corresponding 95%
confidence intervals (CIs). All statistical tests were two-sided with signifi-
cance established at 0.05.
RESULTS
Table 1 reports descriptive statistics for the sample, including
all variables used in the Cox regression analyses. At baseline,
the sample of CGs ranged in age from 56 to 90 years
(M (SD) = 74.20 (7.99) years) and was 80% female. The mean
length of time for participation was 326.5 days, and only 3.5%
participants had made an ED visit in the 30 days before enrollment.
IL-6 demonstrated significant positive skewness and a log transfor-
mation was conducted to reduce skew and log-transformed IL-6
was used in all subsequent analyses.
Association of IL-6 With ED Use
Because one participant was censored at 72 days, before the earli-
est ED visit for the sample, this case was excluded from the Cox
regression analysis of ED use, leaving a total sample size of 85 par-
ticipants. Of these participants, 12 (14.0%) experienced an ED
visit during the 15-month follow-up period. Results of our initial
TABLE 1. Sample Characteristics by 15-mo Follow-up ED Use
With ED Visit (n = 12) Without ED Visit (n = 74)
Variables n (%) Range n (%) Range t Score; χ2 p
Age, M (SD), y 74.5 (9.6) 56–88 74.1 (7.8) 56–90 0.13 .90
Female 10 (83.3) 59 (79.7) 0.09 .77
Race/ethnicity
White, non-Hispanic 9 (75.0) 60 (81.1) .60*
Hispanic 2 (16.7) 7 (9.4)
Black 1 (8.3) 3 (4.1)
Asian/Pacific Islander 0 (0.0) 4 (5.4)
BMI, M (SD), kg/m2 28.9 (4.2) 21.6–35.3 27.1 (5.1) 18.3–45.0 1.17 .25
Previous ED visit 2 (16.7) 1 (1.4) .05*
Hypertension 5 (41.7) 31 (41.9) 0.00 >.99
Heart disease 1 (8.3) 3 (4.1) .46*
Diabetes 3 (25.0) 7 (9.5) .14*
Liver disease 0 (0.0) 2 (2.7) >.99*
Kidney disease 3 (25.0) 5 (6.8) .079*
ADLQ score, M (SD) 72.8 (16.4) 42.3–98.7 66.1 (18.6) 16.7–96.0 1.18 .24
SF-12 PCS, M (SD) 42.7 (12.5) 23.2–63.5 50.2 (11.0) 21.1–67.0 −2.14 .035
SF-12 MCS, M (SD) 46.2 (12.6) 23.7–64.1 46.2 (8.9) 22.7–63.4 −0.02 .99
IL-6, M (SD), pg/ml 2.7 (4.3) 0.6–16.1 0.9 (0.7) 0.2–4.4 3.40 .001
ED = emergency department; M = mean; SD = Standard deviation; BMI = body mass index; ADLQ = Activities of Daily Living Questionnaire; PCS = physical composite score;
MCS = mental composite score; IL-6 = interleukin 6; SF-12 = short form-12.
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(unadjusted) Coxmodel showed that log IL-6 was significantly as-
sociated with ED visits (B = 2.53, SE = 0.67, HR = 12.52,
HR = 3.36–46.64, p < .001). Results of the adjustedmodel are pre-
sented in Table 2. In this analysis, previous ED visit (B = 3.06,
SE = 1.17, p = .009), CG demands (B = 0.042, SE = 0.021,
p = .042), and IL-6 levels (B = 1.96, SE = 0.82, p = .017) signifi-
cantly predicted ED visit. The HR data suggest that those CGs
who had an ED visit 1 month before enrollment (n = 3) were at
21 times the risk of another visit during the follow-up period.
For every point increase in CG demands, CGs experienced a
4.3% increased risk of an ED visit. Finally, each log picogram
per milliliter increase in IL-6 was associated with a seven-fold in-
creased risk of an ED visit.
In the primary analyses, TNF-αwas not associated with ED visits
and therefore not further examined in the exploratory analyses.
Exploratory Analyses
We conducted several follow-up analyses. First, we examined the
interaction between CG demands and IL-6 levels to determine
whether CGs at higher levels of IL-6 combined with higher levels
of CG demands were more likely to use EDs. Because CGs with
lower relative levels of IL-6 (e.g., 50th–60th percentile) were
deemed less likely to make use of EDs, we sought to determine
the value at which IL-6 crossed from “nonsignificance” to signifi-
cance. We conducted two analyses in this regard. The first exam-
ined the interaction between linear ADLQ scores and log IL-6.
Results of this analysis indicated that there was not a significant in-
teraction (B = −0.048, SE = 0.067, Wald = 0.52, df = 1, p = .471).
We then also conducted a median split of IL-6, whereby two
groups were created at the 50th percentile to denote “high” versus
“low” IL-6 values. We then replicated our original Cox propor-
tional hazards analysis using this IL-650 variable in the model. If
not significant, we continued these analyses by increasing our
“high versus low” IL-6 split in 10-percentile increments, until
IL-6 significantly predicted ED visits. Results of these analyses in-
dicated that IL-6 became a significant predictor of ED visit at the
80th percentile (B = 1.72, SE = 0.69, Wald = 6.32, df = 1,
p = .012), corresponding to an IL-6 value of 1.30 pg/ml (see sur-
vival plot in Figure 1).
Given the independent associations of both CG demands and
IL-6 with ED risk, we conducted follow-up, exploratory analyses
examining the combination of these factors for predicting ED visit.
In this analysis, we examined the interaction between linear
ADLQ scores and log IL-6. Results of this analysis indicated no
significant interaction between CG demands (ADLQ scores) and
IL-6. Then, as mentioned previously, we conducted exploratory
analyses using the IL-680 variable from the previous analysis to
create “high” versus “low” IL-6 groups. We also created “high”
versus “low” demand groups, whereby care receiver with mild
or moderate ADLQ scores were “low” demand group, and those
with “severe” functional disability were the “high” demand group.
Then, we combined these factors to make four groups as follows:
(a) low demand, low IL-6 (reference group; n = 30), (b) low de-
mand, high IL-6 (n = 7), (c) high demand, low IL-6 (n = 39),
and (d) high demand, high IL-6 (n = 9). We then repeated our orig-
inal Cox proportional hazards model with this variable to predict
ED visit. Unfortunately, coefficients did not converge for this
model. Further exploration of the failure revealed this failure to
converge was due to the fact that zero CGs in our reference group
(low demand, low IL-6) experienced an ED visit during the
15-month follow-up. Raw data on the number of events per group
were as follows: (a) low demand, low IL-6 (reference group;
n = 0), (b) low demand, high IL-6 (n = 3), (c) high demand, low
IL-6 (n = 5), and (d) high demand, high IL-6 (n = 4). Visual
TABLE 2. Survival Analyses Model Results
B SE Wald df p HR (95% CI)
Age 0.03 0.05 0.29 1 .592 1.03 (0.93–1.13)
Female 0.65 0.95 0.47 1 .495 1.91 (0.30–12.28)
BMI, kg/m2 0.02 0.07 0.11 1 .738 1.02 (0.89–1.18)
Prior ED use 3.06 1.17 6.86 1 .009 21.41 (2.16–212.00)
SF-12 PCS −0.06 0.03 3.09 1 .079 0.94 (0.89–1.01)
SF-12 MCS 0.01 0.04 0.02 1 .888 1.01 (0.93–1.08)
ADLQ 0.04 0.02 4.12 1 .042 1.04 (1.00–1.09)
(log) IL-6 1.96 0.82 5.75 1 .017 7.10 (1.43–35.28)
SE = standard error; HR = hazard ratio; CI = confidence interval; BMI = body mass
index; ED = emergency department; PCS = physical composite score; MCS = mental
composite score; ADLQ = Independent Activities of Daily Living Questionnaire;
IL-6 = interleukin 6.
Statistical results are for Cox proportional hazards model.
FIGURE 1. ED survival for CGs with “high” versus “low” IL-6. A total of 86 participants were available at the 3-month follow-up, 66 at
the 9-month follow-up, and 45 at the 15-month follow-up.
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inspection of results showed a pattern of risk as follows: (a) lowest
risk among individuals with low demand, low IL-6 (100% free of
ED visit), (b) high IL-6, low demand (~88% free of ED visit), (c)
high demand, low IL-6 (approximately 81% free of ED visit, and
(d) high demand, high IL-6 (~43% free of ED visit). For graphical
depiction of these results, see Figure 2).
Association of IL-6 With Caregiver Hospitalization
Three participants were censored before the earliest hospitalization
event for the sample and were subsequently excluded from the
Cox regression analyses, leaving a total sample size of 83 partici-
pants. Of these, five (5.8%) experienced a hospitalization during
the 15-month follow-up period. Results of our initial (unadjusted)
Cox model (B = 1.375; HR = 3.955, 95% CI = 0.268–58.277,
p = .316) as well as the adjusted model (B = 0.773, HR = 2.167,
95% CI = 0.115–40.735, p = .605) showed that log IL-6 was not
significantly associated with hospitalization. In this model, only fe-
male sex was significantly associated with hospitalization, whereby
females were less likely to experience hospitalization than males
(B = −3.068, HR = 0.047, 95% CI = 0.004–0.589, p = .018).
DISCUSSION
Results of this study support our hypothesis that circulating IL-6
levels significantly predict the risk for ED visit in CGs of those
with dementia, independent of potential confounding factors includ-
ing age, sex, recent ED visit, physical and mental well-being, and
BMI. These results suggest that IL-6, whether associated with
nonspecific symptoms or with some disease state, may predict
ED utilization. In addition, CGs experiencing high demands
(i.e., providing care for a care receiver with more severe functional
disability) were at significant risk of experiencing an ED visit. In
addition, because of our inclusion/exclusion criteria, our sample
was relatively healthy and free of chronic illness. Therefore, our
results are not restricted only to people experiencing specific dis-
eases but more broadly relate to healthy individuals as well. Un-
like for IL-6, TNF-α did not emerge as a predictor of ED visit.
Although TNF-α is also a marker of systemic inflammation, one
explanation for this discrepancy could be that TNF-α has much
less consistently been associated with prefrailty and frailty in older
adults than IL-6 (44). Frailty denotes a state of vulnerability to
poor resolution of homeostasis after everyday stressors resulting
in a cumulative decline in many physiological systems (45),
thereby increasing the risk of ED visits (46).
These results are clinically interesting because IL-6 may serve
as a predictor of ED use in an older adult population that has the
highest utilization rate of these costly outpatient services. Explor-
atory analyses from this study indicated that IL-6 levels of 1.3 pg/ml
or greater were prospectively associated with increased risk of
ED visit. Although we urge caution, this may serve as a prelim-
inary benchmark for clinical use of IL-6 in determining health risk
in this population or as a benchmark for future research studies in
determining risk in this and other older adult (non-CG) popula-
tions. Although IL-6 elevations could be due to several causes,
valid prediction of who needs greater services could lead to better
preventative care and reduce healthcare costs. Furthermore, CGs
facing higher caregiving demands, such as taking care of care re-
ceivers with greater functional impairment, may be at even higher
risk of ED visit. An exploratory analysis examining the interaction
between CG demands (i.e., ADLQ scores) and IL-y6 was nonsig-
nificant, suggesting that IL-6 may not exert stronger effects at dif-
ferent levels of CG demand. However, this interaction had low
statistical power, and future studies with increased power should
further examine this potential effect.
Multiple interventions have been shown to help decrease
stress-related biomarkers and improve outcomes that often accom-
pany high CG demand. For example, a behavioral activation inter-
vention termed the Pleasant Events Program significantly reduced
IL-6 levels and depressive symptoms among spousal CGs
compared with an informational-support control condition (40).
Another study found that CGs receiving a group cognitive-behavioral
intervention experienced a significant reduction in daily sali-
vary cortisol secretion compared with those in an educational
intervention (47). Likewise, mindfulness-based stress reduction
interventions may benefit CGs by reducing depression, CG bur-
den, and increasing quality of life (48), and mindfulness-based
stress reduction has been shown to significantly reduce IL-6 se-
cretion in response to acute stressors (49). In addition to cognitive-
behavioral interventions, respite services, such as home help and
adult day care, may help reduce stress and alleviate CG burden
(50). Future research should continue to examine the role of stress
reduction interventions on inflammation biomarkers, such as IL-6,
and determine the impact of these interventions on healthcare ser-
vice use.
This study has several limitations. First, the CG population was
racially homogenous (80.2% white) and consisted of adults
55 years and older, limiting the generalizability of our study.
FIGURE 2. ED survival for interaction between CG demand and IL-6. A total of 86 participants were available at the 3-month follow-up,
66 at the 9-month follow-up, and 45 at the 15-month follow-up.
ORIGINAL ARTICLE
Psychosomatic Medicine, V 81 • 668-674 672 September 2019
Copyright © 2019 by the American Psychosomatic Society. Unauthorized reproduction of this article is prohibited.
Second, our study examined the relationship between IL-6 levels
at baseline assessment to 15-month risk of ED visit. Greater under-
standing of ED risk may be gained from more frequent collections
of IL-6 data. Next, ours was limited by a modest sample size and
few ED and hospital visits. Next, IL-6 levels increase with age
and measures are not standardized across laboratories and assess-
ment methods, so cutoffs to identify individuals at risk may be dif-
ferent in younger populations and depend on the IL-6 assay used
(51). These limitations make it necessary to interpret these results
as preliminary, and replication of these results in larger and more
diverse samples is necessary for adequate decision-making in a
clinical context.
Finally, our study focused on spousal dementia CGs. On the
one hand, although the mechanisms by which chronic stresses af-
fect IL-6 may not be unique to dementia caregiving populations,
there are unique elements involved in caring for a loved one with
dementia. For example, the unique nature of caregiving requires
ongoing care that makes avoidance or escape from the stresses
of caregiving a difficult undertaking. The increased reliance of
care recipients on their CGs over time makes respite increasingly
difficult to achieve among caregiving populations. Indeed, the
term “vulnerable CG” has been used to describe CGs who experi-
ence a high degree of demand and low degree of respite (52). Thus,
additional research, possibly with other chronic stress populations
including military personnel or those experiencing work stress
(e.g., firefighters or police), should be conducted to fully under-
stand the nature of these effects. Therefore, our results, particularly
regarding the interaction between IL-6 and CG demand may not
generalize to other populations, such as CGs of patients with other
chronic diseases.
To summarize, higher IL-6 levels significantly predicted risk
for ED visit in dementia CGs in a 15-month period adjusting for
confounding factors including age, sex, recent ED visit, physical
and mental well-being, and BMI. In addition, care receiver func-
tional disability was also significantly associated with increased
risk for ED visit. Exploratory analyses showed a possible interac-
tion between these effects, whereby individuals with higher levels
of IL-6 caring for care receivers with high functional disability
seemed to be at the greatest risk for ED visit during the follow-
up period. Future research should explore whether this relation-
ship holds in samples of other age groups, non-CG populations,
and determine whether early interventions can reduce both IL-6
and ED visit risk.
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Moderators of Response to Cognitive Behavior Therapy for Major Depression in
Patients With Heart Failure: Erratum
In the article published in volume 81 of Psychosomatic Medicine on pages 506–512 (1), an error appeared in the author list. The final
author, Michael W. Rich, was mistakenly listed as Michael W. Carney.
This has been corrected in the online version.
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